On April 30, 2018, the new listing regime published by The Stock Exchange of Hong Kong Limited (the “Exchange”) for companies from emerging and innovative sectors took effect. The new listing regime makes it possible for...more
Historically, the US, and, in particular, the NASDAQ market, has been the predominant place for IPOs of life sciences and healthcare companies. However, 2018 may be the year in which things start to change....more
3/13/2018
/ Capital Markets ,
CFDA ,
China ,
Health Care Providers ,
Hong Kong ,
Hong Kong Stock Exchange ,
Institutional Investors ,
Life Sciences ,
Listing Rules ,
Listing Standards ,
New Rules ,
NYSE ,
Regulatory Oversight